Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 9/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 8/20 | 0.37 |
| ▸ | PPARA | Q07869 | 8/20 | 0.37 |
| ▸ | MMP13 | P45452 | 2/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746469 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1TDP1PPARDLMNA | |
| SCHEMBL1745143 | 0.87 | KDM4E (0.46) | KDM4EALDH1A1TDP1PPARDLMNA | |
| SCHEMBL1745142 | 0.87 | KDM4E (0.46) | KDM4EALDH1A1TDP1PPARDLMNA | |
| SCHEMBL23135324 | 0.87 | KDM4E (0.42) | KDM4EALDH1A1TDP1PPARDLMNA | |
| SCHEMBL1745146 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1TDP1PPARDLMNA | |
| SCHEMBL1746379 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1TDP1PPARDLMNA | |
| SCHEMBL1745140 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1TDP1PPARDLMNA | |
| SCHEMBL29801093 | 0.85 | KDM4E (0.47) | KDM4EALDH1A1TDP1PPARDLMNA | |
| SCHEMBL1746471 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1TDP1PPARDLMNA | |
| SCHEMBL28680141 | 0.84 | PPARD (0.45) | KDM4EALDH1A1TDP1PPARDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386540-A1 | Novel compounds, their preparation and use | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| US-7943613-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | PPARG, PPARA, PPARD | KDM4E 2717/4885ALDH1A1 198/4885TDP1 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.